Caboxen 20 mg (Cabozantinib) Tablets


Caboxen 20 mg (Cabozantinib) Tablets


“Caboxen 20 mg,” a cutting-edge formulation by Everest Pharmaceuticals Ltd. and distributed by Orio Pharma, is a hallmark in the field of advanced cancer therapy. Cabozantinib, its active ingredient, is recognized for its precision in targeting key molecular pathways integral to cancer development and progression.

Development by Everest Pharmaceuticals Ltd.:

Everest Pharmaceuticals Ltd. has been instrumental in the creation of Caboxen 20 mg, exemplifying its commitment to innovative cancer treatments. Cabozantinib, as a tyrosine kinase inhibitor, is the product of extensive research focused on finding effective solutions for hard-to-treat cancers.

Mechanism of Action:

Caboxen 20 mg operates through the inhibition of multiple receptor tyrosine kinases, notably MET, VEGFR, and AXL. These enzymes are crucial in the mechanisms of cancer cell survival, proliferation, and angiogenesis. By selectively targeting these kinases, Caboxen 20 mg disrupts critical signaling pathways, hindering the progression and spread of various cancers.

Clinical Applications:

Caboxen 20 mg is primarily indicated for:

  1. Renal Cell Carcinoma (RCC): It offers a significant treatment option for patients with advanced RCC, especially those who have not responded to previous anti-angiogenic therapy.
  2. Hepatocellular Carcinoma (HCC): For advanced HCC, particularly in patients previously treated with sorafenib, Caboxen provides an effective therapeutic choice.

Dosage and Administration:

The administration of Caboxen is tailored based on the specific cancer type and the patient’s response. It is usually taken orally, with dosage adjustments made by healthcare professionals according to patient health and response to treatment.

Benefits of Caboxen 20 mg:

  1. Precision Targeting: By focusing on multiple tyrosine kinases, Caboxen 20 mg offers a targeted approach to cancer treatment, enhancing efficacy and reducing side effects.
  2. Angiogenesis Inhibition: The suppression of VEGFR by Cabozantinib plays a crucial role in inhibiting angiogenesis, a vital process in tumor growth and metastasis.
  3. Extended Progression-Free Survival: Clinical trials have shown that Caboxen 20 mg improves progression-free survival, offering hope for prolonged disease control in patients with advanced RCC and HCC.

Manufacturing Excellence by Everest Pharmaceuticals Ltd.:

Everest Pharmaceuticals Ltd. is renowned for its high-quality production of pharmaceuticals. The development of Caboxen 20 mg underscores their dedication to producing reliable and effective medications, adhering to the highest industry standards.

Distribution by Orio Pharma:

Orio Pharma’s role in distributing Caboxen 20 mg is vital in ensuring its availability. Their commitment to efficient supply chain management guarantees that this important medication reaches healthcare providers and patients effectively.


Caboxen 20 mg (Cabozantinib) signifies a monumental step forward in the treatment of advanced RCC and HCC. The collaboration between Everest Pharmaceuticals Ltd. and Orio Pharma has resulted in a medication that transcends traditional approaches to cancer care, offering a new horizon of hope for those affected.

The targeted mechanism of Caboxen 20 mg in inhibiting crucial tyrosine kinases highlights its role as a potent and well-tolerated treatment option. This collaboration ensures the highest manufacturing standards and broad accessibility, making a significant impact in the lives of those battling complex cancers.

As the landscape of oncology continues to evolve, Caboxen 20 mg stands as a symbol of progress in delivering more effective, personalized, and compassionate care. It represents the commitment of Everest Pharmaceuticals Ltd. and Orio Pharma to advancing cancer therapy and providing patients with innovative and life-enhancing treatment options.